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Introduction
Small cell lung cancer (SCLC) accounts for approximately 10-
20% of all lung cancers and is frequently associated with rapid 
tumor proliferation and a median survival of less than 3 months 
in untreated patients [1,2]. At diagnosis, the majority of patients 
present with extensive-stage disease (ED). SCLC is highly sensitive to 
chemotherapy, and a combination therapy with cisplatin/carboplatin 
and etoposide or the camptothecin drug, irinotecan is currently 
considered as the standard first-line treatment [3,4]. In patients with 
ED SCLC, chemotherapy produces response rates of 50% to 70% and 
median survival times of 7 to 9 months. However, most tumors will 
relapse after an initial response and nearly all patients will rapidly die 
from chemotherapy-resistant disease. The second-line treatment for 
relapsed SCLC further involves the use of another camptothecin-based 
drug, topotecan, which was shown to improve survival from 14 weeks 
to 26 weeks [1,5-7].
Both irinotecan and topotecan are camptothecin-based drugs. 
Camptothecins (CPT) promote cancer cell death by locking 
topoisomerase I (TOP1) on a DNA single-strand break intermediate 
[8,9]. An unrepaired TOP1-mediated DNA single-strand break is 
converted into the potentially toxic DNA double-strand break upon 
collision with the replication machinery [10]. The repair of these 
hampered TOP1 complexes involve proteasomal degradation of TOP1 
to leave a 3’-phosphotyrosyl peptide that is further processed by the 
3’-phosphodiesterase activity of TDP1 during chromosomal single-
strand break repair [11,12].
The ability of camptothecins (CPT) to kill cancer cells is dependent 
on both TOP1 activity on DNA and the rate of repair of TOP1-DNA 
breaks. Inhibition of TDP1 repair activity is therefore regarded as a 
promising mean for improving the efficacy of camptothecin-based 
drugs in the clinic [12-15]. Indeed, multiple studies have shown 
that inactivation or loss of TDP1 sensitises cells to CPT whereas 
overexpression of TDP1 promotes CPT tolerance [16-20]. Such 
findings additionally imply that high cellular levels of TDP1 may 
contribute to CPT drug resistance in cancer. Multiple drug discovery 
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Abstract
Background and objective: Small cell lung cancer (SCLC) is one of the most challenging tumors to treat due 
to high proliferation rate, early metastatic dissemination and rapid development of chemotherapy resistance. The 
current treatment protocols involve the use of topoisomerase 1 (TOP1) poisons such as irinotecan and topotecan in 
combination with platinum-based compounds. TOP1 poisons kill cancer cells by trapping TOP1 on DNA, generating 
lethal DNA double-strand breaks. A potential mechanism employed by cancer cells to resist killing by TOP1 poisons 
is to overexpress enzymes involved in the repair of TOP1-DNA breaks. Tyrosyl DNA phosphodiesterase 1 (TDP1) 
is a key player in this process and despite its importance, no data is currently available to correlate TDP1 protein 
and mRNA levels with catalytic activity in SCLC. In addition, it is not known if TDP1 and TOP1 protein levels 
correlate with the cellular response of SCLC to TOP1 based therapies.
Methods and results: We report a remarkable variation in TDP1 and TOP1 protein levels in a panel of SCLC 
cell lines. TDP1 protein level correlates well with TDP1 mRNA and TDP1 catalytic activity, as measured by two 
newly developed independent activity assays, suggesting the potential utility of immunohistochemistry in assessing 
TDP1 levels in SCLC tissues. We further demonstrate that whilst TDP1 protein level alone does not correlate 
with topotecan sensitivity, TDP1/TOP1 ratio correlates well with sensitivity in 8 out of 10 cell lines examined. 
Conclusion: This study provides the first cellular analyses of TDP1 and TOP1 in SCLC and suggests the 
potential utility of TDP1/TOP1 ratio to assess the response of SCLC to topotecan. The establishment and validation 
of an easy-to-use TDP1 enzymatic assay in cell extracts could be exploited as a diagnostic tool in the clinic. These 
findings may help in stratifying patients that are likely to benefit from TOP1 poisons and TDP1 inhibitors currently 
under development.
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projects attempting to develop TDP1 inhibitors are currently underway 
and though some inhibitor structures have been identified, there are 
no validated cellular or in vivo models for confirming inhibitor hits or 
clinical trials in progress [21-24].
TOP1 levels are widely accepted to predict sensitivity to 
camptothecin in a large number of cancer types [25,26]. In contrast, 
little is known about the correlation between TDP1 or TDP1/TOP1 
ratio and sensitivity to camptothecin-based therapies. Such an 
understanding would be particularly informative in selecting cancer 
types that could benefit from TDP1 inhibition in future clinical trials. 
Suitable candidates include cancers such as SCLC that are currently 
treated with camptothecin derivatives. Therefore, in this study we 
aimed to characterise both TDP1 and TOP1 status in a panel of SCLC 
cell lines and to examine the relationship between TDP1 transcript 
level, protein level, activity, and sensitivity to the camptothecin 
derivative, topotecan. 
We report a remarkable variation in both TDP1 and TOP1 levels 
in SCLC lines. TDP1 protein levels correlate well with both TDP1 
mRNA and TDP1 catalytic activity. We further show that whilst TDP1 
protein level alone does not significantly correlate with topotecan 
sensitivity, TDP1/TOP1 ratio correlates well in 8 out of 10 SCLC cell 
lines examined, suggesting the potential utility of this ratio to assess 
topotecan sensitivity in SCLC.
Materials and Methods
Cells
The small cell lung cancer lines HCC33, H69, N417, H2171, H209 
and H510 and the non-small cell lung cancer lines Hop62, Hop92, 
HCC78, H322M and H23 were obtained from Professor Peter Schmid. 
The remaining SCLC lines, H82, H187, H146 and H345 were bought 
from ATCC (ATCC, Virginia, USA). Mammalian cells were grown in a 
37°C, 5% CO2 incubator. The small cell lung cancer lines HCC33, H69, 
N417, H2171, H209, H510, H82 and H187 were grown in Gibco RPMI 
media (Life Technologies, Paisley, UK) supplemented with 10% FCS 
and 2 mM L-glutamine. The H146 cell line was grown in Gibco RPMI 
supplemented with 10% FCS, 2 mM L-glutamine, 10 mM HEPES, 1 mM 
sodium pyruvate, 4.5 g/L glucose and 1.5 g/L sodium bicarbonate. The 
H345 cell line was grown in Gibco RPMI supplemented with 20% FCS, 4 
mM L-glutamine, 10 mM HEPES and 1.5 g/L sodium bicarbonate. The 
non-small cell lung cancer lines Hop62, Hop92, HCC78, H322M and 
H23 were maintained in Gibco RPMI (Life Technologies, Paisley, UK) 
supplemented with 10% FCS and 2 mM L-glutamine and the HCC193 
cell line was maintained in Gibco DMEM (Life Technologies, Paisley, 
UK) containing 10% FCS and 2 mM L-glutamine. The generation and 
characterisation of the DT40 Tdp1-/- chicken cells and the DT40 Tdp1-
/- chicken cells stably expressing human TDP1 have been described 
recently [12,16,17,20,22-31]. The DT40 chicken cells were maintained 
at 39°C, 5% CO2, in Gibco RPMI (Life Technologies, Paisley, UK) 
supplemented with 10% FCS, 1% chicken serum, 100 U Penicillin, 100 
µg Streptomycin, 2 mM L-glutamine and 50 µM β-mercaptoethanol. 
Whole cell extract preparation
Cells were collected by centrifugation (DT40 and small cell lung 
cancer suspension lines) or by scraping (non-small cell lung cancer 
adherent lines) and washed twice in ice cold phosphate buffered saline 
(PBS). Cell pellets were resuspended in ice-cold lysis buffer (20 mM 
Tris-HCl pH 7.5, 10 mM EDTA pH 8.0, 100 mM NaCl, 1% Triton 
X-100) containing the recommended final concentration of Complete 
Mini EDTA-free Protease Inhibitor Cocktail (Roche Applied Science, 
Burgess Hill, UK). Samples were briefly vortexed and extraction carried 
out for 30 min on ice. The lysate was cleared by centrifugation at 13,000 
rpm for 10 min and the supernatant collected as whole cell extract 
(WCE). Protein concentration was calculated using Bradford assay and 
samples stored at -80°C.
Western blotting
Protein separation of WCE (40 µg) was carried out by 10% SDS-
polyacrylamide gel electrophoresis (PAGE) at 125 V for 2 hr. The 
separated proteins were subsequently transferred onto a Hybond-C 
Extra Nitrocellulose membrane (Fisher Scientific UK, Loughborough, 
UK) at 25 V for 90 min. Membranes were blocked in 5% PBS-milk 
for 1 hr prior to immunoblotting overnight with antibodies against 
TDP1 (ab4166; Abcam, Cambridge, UK), TOP1 (SC-32736; Santa 
Cruz Biotechnologies, California, USA) and actin (A4700; Sigma-
Aldrich, Gillingham, UK) diluted in 5% PBST-milk to 1:2000, 1:1000 
and 1:3000, respectively. HRP-labelled polyclonal rabbit anti-mouse 
and polyclonal goat anti-rabbit secondary antibodies obtained from 
Dako (Ely, UK) were used at a 1:3000 dilution in 5% PBST-milk. 
Blots were developed using the chemiluminescent detection reagent, 
SuperSignal West Pico Chemiluminescent Substrate (Fisher Scientific 
UK, Loughborough, UK).
TDP1 activity assay: Gel-based assay
The in vitro 3’-tyrosyl-DNA phosphodiesterase activity of SCLC 
whole cell extracts (WCE) was determined using a gel-based 3’-tyrosyl-
DNA phosphodiesterase activity assay. Reactions were performed in 
10 µL reaction volumes containing assay buffer (25 mM HEPES, pH 
8.0, 130 mM KCl, 1 mM DTT), WCE (20 ng and 25 ng) and 50 nM 
Cy5.5 labelled substrate oligomer containing a 3’-phosphotyrosyl 
group, 5’-(Cy5.5)GATCTAAAAGACT(pY)-3’ (Midland Certified 
Reagent Company, Texas, USA). Reactions were carried out at 37°C 
for 1 hr and stopped by addition of 10 µL loading buffer (44% deionized 
formamide, 2.25 mM Tris-borate, 0.05 mM EDTA, 0.01% xylene 
cyanol, 1% bromophenol blue). Samples were then heated at 90°C for 
10 min prior to separation on a 20% Urea SequaGel (Fisher Scientific, 
Loughborough, UK) by gel electrophoresis at 190 V for 2 hr. Reaction 
products were visualised by gel imaging using the Fuji Film Fluor 
Imager FLA-5100 at 635 nm and bands quantified using Image J. 
TDP1 activity assay: Fluorescence assay
In vitro 3’-tyrosyl-DNA phosphodiesterase activity of whole 
cell extracts (WCE) was determined using our recently developed 
fluorescence assay [21]. Briefly, assays were performed in a 15 µl 
reaction volume containing assay buffer (50 mM Tris pH 8.0, 5 mM 
MgCl2, 80 mM KCl, 0.05% Tween 20, 1 mM DTT), 10 nM 13-mer 
substrate with a 3’-phosphotyrosyl oligonucleotide conjugated to a 
FITC molecule (Midland Certified Reagent Company, Texas, USA) 
and 2 µl of the indicated amounts of WCE. Reactions were carried 
out at room temperature for 10 min prior to quenching with a mix of 
30 µl enhancer and 2 µl sensor (Gyrasol Technologies, Kansas, USA). 
Fluorescence intensity was measured using a BMG Labtech Pherastar 
plate reader at excitation and emission wavelengths of λex 490 nm and 
λem 520 nm. Recombinant human TDP1 (6.5 pM)  [21] diluted in assay 
buffer was used as a 3’-tyrosyl-DNA phosphodiesterase activity control 
for the reactions between independent experiments. 
Quantitative PCR
Total mRNA was purified from cells using the RNeasy kit (Qiagen, 
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Crawley, UK) according to the manufacturer’s instructions. The 
mRNA concentration was determined using the NanoDrop 1000 
spectrophotometer (Nanodrop, Willmington, USA) at OD 230 nm. 
cDNA was generated from 1 µg mRNA using the Superscript First 
Strand RT-PCR system (Invitrogen, Paisley, UK) and real time PCR 
analysis was carried out on the MX3005p qPCR system (Agilent 
Technologies, Santa Clara, USA) using Blue qPCR Sybr low ROX mix 
(Fisher Scientific, Loughborough, UK) for cDNA amplification. The 
average cycle threshold for three readings per each of three repeat 
experiments was used in further calculations to determine the relative 
quantities of mRNA (RQ) according to the equation RQ=2ΔΔCT. 
CellTiter-Blue cell viability assay
The CellTiter-Blue cell viability assay (Promega, Southampton, UK) 
was used to determine SCLC cell sensitivity to topotecan hydrochloride 
hydrate (Sigma-Aldrich, Gillingham, UK). Briefly, cells were seeded in 
triplicate at 10,000 cells per well of a 96-well plate in media containing 
topotecan (0 nM to 500 nM). The contents were mixed thoroughly and 
the plates incubated at 37°C for 4 days. At day 4, CellTiter-Blue reagent 
(20 µl) was added to each well, the plates incubated at 37°C for 2 hr and 
fluorescence intensity determined using the GloMax Multi Detection 
System (Promega, Southamption, UK) at excitation and emission 
wavelengths of λex 560 nm and λem 590 nm. Percentage viability (%) was 
calculated using background-subtracted readings as: 
(Fluorescence readtreated/Fluorescence readuntreated) * 100%.
Results
TDP1 is viewed as a promising target for inhibition in cancers 
such as SCLC that are currently treated with camptothecin-based 
therapies. Since topoisomerase I (TOP1) is generally thought to dictate 
the sensitivity of cancers to camptothecin, we sought to determine the 
cellular level of both TDP1 and TOP1 in a panel of SCLC cell lines 
(HCC33, H69, N417, H2171, H209 and H510). Separation of 40 µg of 
whole cell extracts (WCE) for each of the SCLC cell lines by 10% SDS-
PAGE and analysis by Western blotting using TDP1 and TOP1 specific 
antibodies revealed a significant variation in both TDP1 and TOP1 
protein level (Figure 1A-C). Interestingly, we noticed that SCLC lines 
possess higher levels of TDP1 compared to non-small cell lung cancer 
lines (HCC193, Hop62, Hop92, HCC78, H322M and H23; Figure 1A), 
suggesting that TDP1 may play a role in the biology, progression and, 
in particular, the therapeutic response of SCLC to camptothecin-based 
treatments. 
Cellular protein levels are maintained by both transcriptional and 
post-translational regulation. To determine the nature of the variation 
in cellular TDP1 and TOP1 protein levels in SCLC, cellular mRNA levels 
for both TDP1 and TOP1 were determined by quantitative real-time 
PCR using primers designed against exon-crossing regions for TDP1 
and TOP1 cDNA (Figure 2A and 2C). Since there is no real isogenic 
control gene between the cell lines, the relative quantifications were 
obtained by normalising mRNA levels to that obtained for HCC33 for 
TDP1 mRNA measurements, or H510 for TOP1 mRNA. We further 
determined the Pearson’s correlation coefficient between mRNA and 
protein levels for both TDP1 and TOP1 to examine the relationship 
between mRNA and protein levels (Figure 2B and 2D). We observed a 
positive correlation between TDP1 mRNA and TDP1 protein (r=0.681, 
p=0.136) and a slightly weaker correlation between TOP1 mRNA and 
TOP1 protein (r=0.519, p=0.292). 
Post-translational modifications may further dictate the cellular 
activity of TDP1 [11,16,18,19,32]. It is therefore important to examine 
whether cellular TDP1 protein levels correlate with its activity, 
which is critical for designing a suitable diagnostic tool for selecting 
tumors that could benefit from TDP1 inhibitor-based therapies. To 
test this, we employed two orthogonal enzymatic assays; a gel-based 
assay and a fluorescence-based assay that was recently developed 
in our labs [21]. For the gel-based assay we engineered a 5’-Cy5.5 
labelled substrate containing a 3’-phosphotyrosine modification 
(Figure 3A), thus introducing a unique imaging opportunity that 
does not involve the bothersome radioactive based methods that we 
used previously [11,17,18]. Whole cell extracts prepared from the 
SCLC cell lines were used as a source for TDP1 activity and reaction 
products were subsequently separated on a 20% denaturing PAGE by 
gel electrophoresis, and then visualised using a FujiFilm Fluor Imager 
FLA-5100 at 635 nm (Figure 3B). The relative activity was calculated 
by normalising the percentage cleavage to that obtained for 20 ng 
HCC33 whole cell extract and results obtained from three biological 
replicates are shown in Figure 3C. The results demonstrate a positive 
Figure 1: Small cell lung cancer cell lines display remarkable variation 
in both TDP1 and TOP1 protein level. (A) Whole cell extracts (40 µg) from 
the indicated small cell lung cancer cell lines and other non-small cell lung 
cancer cells were separated by 10 % SDS-PAGE and immunoblotted using 
antibodies against TDP1, TOP1 and actin. A quantitation of relative TDP1 (B) 
and TOP1 (C) protein level is depicted. Data are the average of 3 independent 
experiments ± STD normalised to HCC33 for TDP1 and H510 for TOP1.
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correlation between TDP1 protein level and TDP1 activity in SCLC cell 
lines (r=0.700, p=0.121 for 20 ng WCE; and r=0.747, p=0.088 for 25 ng 
WCE) (Figure 3D and 3E). These observations are in agreement with a 
recent study by the Pommier group on NSCLC reporting a remarkably 
similar positive correlation (r=0.75) between TDP1 protein level and 
catalytic activity [33].
To better understand the relationship between TDP1 protein 
level and cellular activity, we additionally employed our recently 
developed fluorescence assay [21]. This 384-well plate format assay 
uses a FITC-conjugated 13-mer 3’-phosphotyrosyl substrate that 
releases a fluorescence signal upon processing (Figure 4A). We first 
examined whether this new assay would be reliable in determining 
TDP1 enzymatic activity in whole cell extracts. To test this, we 
generated chicken DT40 Tdp1-/- cells stably expressing low and high 
levels of human TDP1 and examined whether TDP1 level correlates 
with enzymatic activity. Whilst extracts from DT40 Tdp1-/- cells had 
no detectable TDP1 activity, incubation of the TDP1 substrate with 
increasing concentrations of whole cell extract prepared from DT40 
Tdp1-/- cells expressing human TDP1 led to a proportional increase 
in TDP1 activity as measured by relative fluorescence (Figure 4B and 
4C). These observations validate the assay and suggest its robustness 
in determining TDP1 activity in cellular extracts. We next examined 
whole cell extracts (0.25 ng) generated from the SCLC cell lines using a 
recombinant TDP1 protein (6.5 pM) as a control. The relative activity 
obtained for each cell line (Figure 4D) was calculated by normalising the 
fluorescence intensity against that obtained for recombinant TDP1 for 
three independently generated extracts. These results illustrate a clear 
variation in TDP1 activity in SCLC and, importantly, the Pearson’s 
correlation coefficient (r=0.86, p=0.028) suggests a significant positive 
correlation between cellular TDP1 activity and protein level (Figure 
4E). 
TDP1 is a key repair factor responsible for resolving TOP1-linked 
DNA breaks generated by camptothecin and its derivatives [17,20]. It 
was therefore of interest to understand the relationship between TDP1 
levels and sensitivity of SCLC to the camptothecin drug, topotecan that 
is currently used in the clinic to treat relapsed SCLC. Cell viability in 
the presence or absence of topotecan (TPT) was determined using the 
CellTiter-Blue viability reagent. Cells were treated with a concentration 
range of topotecan (0 nM to 500 nM) and grown for four days prior 
to analysis from which percentage viability (Figure 5A) and the 
Pearson’s correlation coefficient between TDP1 protein level and 
topotecan sensitivity (Figure 5B) were calculated. We observed a weak 
positive correlation between TDP1 level and viability at all topotecan 
concentrations analysed (Figure 5B and Table 1). Following topotecan 
treatment, TDP1 exclusively repairs TOP1 mediated DNA breaks, thus 
we reasoned that the weak correlation might be due to variations in 
TOP1 levels. Indeed, subsequent analyses revealed a stronger negative 
correlation between TOP1 levels and topotecan sensitivity (Figure 5C), 
demonstrating that TOP1 is an important player in determining the 
response of SCLC to topotecan. To account for variations in TOP1 levels 
that may explain the weak correlation between TDP1 and topotecan 
sensitivity, we normalised TDP1 to TOP1 protein levels (TDP1/TOP1) 
for further analysis. This normalisation revealed a modest increase 
Figure 2: Small cell lung cancer cell lines display good correlation between TDP1 or TOP1 protein level and mRNA. cDNA from each of the SCLC lines was 
generated from 1 µg purified mRNA using the Superscript First Strand RT-PCR and real time PCR analysis was conducted using TDP1 primers (A) or TOP1 primers 
(C) and an MX3005p qPCR system. The relative quantity of mRNA (RQ value) for each repeat experiment was calculated according to the equation RQ = 2ΔΔCT and 
the RQ values normalised to that obtained for the HCC33 cell line. The average of normalised RQ values from 3 independent experiments ± STD is depicted (A&C). 
A graphical representation of the Pearson’s correlation coefficient (r) between SCLC TDP1 protein levels and TDP1 mRNA is shown in (B) and that for SCLC TOP1 
protein level and TOP1 mRNA is shown in (D).
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in the positive correlation between TDP1 and topotecan sensitivity 
(Figure 5D, solid line). Interestingly, the cell line H69 that expresses 
the highest level of TDP1 and the lowest level of TOP1 unexpectedly 
exhibited relatively high topotecan sensitivity. Repeating the analyses 
without this outlier cell line revealed a strong positive correlation 
between TDP1/TOP1 and topotecan sensitivity in the five remaining 
cell lines (Figure 5D, dotted line and Table 1).
Figure 3: TDP1 catalytic activity (Gel-based assay) correlates with the level of TDP1 protein in SCLC cells. (A) Diagrammatic representation of TDP1 processing 
of a Cy5.5 labelled oligonucleotide harbouring a 3’-phosphotyrosine modification. The product of a TDP1 reaction is a Cy5.5 labelled oligonucleotide with 3’-phosphate. 
(B) The indicated amounts of WCE (20 ng and 25 ng) were incubated with 50 nM substrate in assay buffer at 37°C for 1 hr.  Reaction products were separated on 
a 20% Urea SequaGel by gel electrophoresis at 190 V for 2 hr and visualised using a FujiFilm Fluor Imager FLA-5100 at 635 nm. Arrows denote the position of the 
substrate (PY) and cleaved product (P). (C) Quantification of the average relative TDP1 activity normalised to that obtained from HCC33 cell line from 3 independent 
experiments ± STD. Recombinant TDP1 (8 pM) was employed as a positive control. (D) A graphical representation of the Pearson’s correlation coefficient (r) between 
TDP1 protein level and activity.
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To examine if these findings are restricted to the 5 SCLC lines 
employed above, we obtained and analysed four additional SCLC 
lines. TDP1 and TOP1 protein level for each cell line was determined 
by Western blotting (Figure 6A-C) and the corresponding topotecan 
sensitivity was measured as percentage viability using the CellTiter-
Blue cell viability assay (Figure 6D). These analyses revealed that the 
majority of SCLC cell lines (8 out of 10) showed a strong and significant 
positive correlation (r=0.94139, p=0.000491) between TDP1/TOP1 
ratio and topotecan sensitivity (Figure 6E, dotted line and Table 1) with 
2 hypersensitive outliers, H69 and H187 that intriguingly possess the 
highest level of TDP1 (Figure 6E, solid line). These data suggest TDP1/
TOP1 ratio as a useful indicator for the response of SCLC to topotecan 
Figure 4: TDP1 catalytic activity (Fluorescence assay) correlates with the level of TDP1 protein in SCLC cells.  (A) A Metal ion sensor (indicated S) along 
the phosphate backbone of the substrate oligomer keeps the bound FITC-conjugated tyrosine in a non-fluorescent state (OFF). During a TDP1 driven reaction, the 
FITC conjugated tyrosine is released and distance generated between the released FITC-tyrosine and the oligonucleotide increases, allowing for FITC fluorescence 
(ON) that can be detected and quantified using a fluorescence imager. (B) A 15 µl final volume reaction containing 0.5 µg or 1.0 µg WCE from the indicated DT40 
cell lines and 10 nM substrate was incubated for 10 min at room temperature. Reactions were stopped by addition of a reaction quencher and fluorescence intensity 
was measured using a BMG Labtech Pherastar plate reader at excitation and emission wavelengths of λex 490 nm and λem 520 nm. Fluorescence was normalised to 
that obtained for recombinant human TDP1 (6.5 pM) and data represent the average of 3 independent experiments ± STD. (C) Whole cell extracts (40 µg) from the 
indicated DT40 cell lines were separated by 10% SDS-PAGE and immunblotted using antibodies against TDP1 and actin. (D) A 15 µl final volume reaction containing 
0.5 µg SCLC WCE and 10 nM substrate was incubated for 10 min at room temperature. Reactions were stopped by addition of a reaction quencher and fluorescence 
intensity was measured using a BMG Labtech Pherastar plate reader at excitation and emission wavelengths of λex 490 nm and λem 520 nm. Average fluorescence 
was normalised to that obtained for recombinant human TDP1 (6.5 pM), and data represent the average of 3 independent experiments ± STD. (E) A graphical 
representation of the Pearson’s correlation coefficient (r) between SCLC TDP1 protein level and TDP1 activity from 0.5 µg WCE.
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Figure 5: TDP1 and TOP1 levels modulate the cellular response of SCLC to topotecan. (A) The indicated SCLC cell lines were seeded in triplicate at 10,000 
cells per well in a 96-well plate in 100 µl media containing the indicated concentration of topotecan (TPT) and incubated at 37°C for 4 days. Viability was assessed by 
adding 20 µL of the CellTiter-Blue viability assay reagent to wells on day 4, followed by 2 hour incubation at 37°C. Fluorescence was determined using a GloMax Multi 
Detection System (Promega, Southamption, UK) at excitation and emission wavelengths of λex 560 nm and λem 590 nm, respectively. For each cell line, percentage 
viability (%) was calculated as [(Fluorescence readtreatment/Fluorescence readuntreated)*100%] and the graphical representation shows the results obtained from three 
independent experiments ± STD. Graphical representations depicting Pearson’s correlation coefficient (r) between viability at the indicated TPT concentrations and 
TDP1 (B), TOP1 (C), or TDP1/TOP1 levels (D). The solid line represents the correlation coefficient for all six SCLC cell lines whereas the dotted line represents 
the correlation coefficient for the five SCLC cell lines HCC33, N417, H2171, H209 and H510, excluding H69 (triangle), which exhibits high levels of TDP1 and an 
unexpected hypersensitivity to topotecan.
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Pearson’s Correlation Coefficient (r) Probability (p) (2-tailed)
TDP1/TOP1 and Viability (%) 120 nM TPT, n=8 (No H69 or H187) 0.941 0.000491
TDP1/TOP1 and Viability (%) 120 nM TPT, n= 5 (No H69) 0.949 0.014
TDP1/TOP1 and Viability (%) 60 nM TPT, n=5 (No H69) 0.948 0.014
TDP1/TOP1 and Viability (%) 250 nM TPT, n=5 (No H69) 0.945 0.154
TDP1 protein and TDP1 ac,vity-Gyrasol, n=6 0.861 0.028
TDP1 protein and TDP1 ac,vity-GB assay 25 ng, n=6 0.747 0.088
TDP1 protein and TDP1 ac,vity-GB assay 20 ng, n=6 0.703 0.121
TOP1 protein and Viability (%) 250 nM TPT, n=6 -0.695 0.125
TOP1 protein and Viability (%) 120 nM TPT, n=6 -0.692 0.127
TOP1 protein and Viability (%) 60 nM TPT, n=6 -0.686 0.133
TDP1 protein and TDP1 mRNA, n=6 0.681 0.136
TOP1 protein and Top1 mRNA, n=6 0.519 0.292
TDP1/TOP1 and Viability (%) 250 nM TPT, n=6 0.451 0.369
TDP1/TOP1 and Viability (%) 120 nM TPT, n=6 0.411 0.418
TDP1/TOP1 and Viability (%) 60 nM TPT, n=6 0.387 0.448
TDP1 protein and Viability (%) 250 nM TPT, n=6 0.402 0.429
TDP1 protein and Viability (%) 120 nM TPT, n=6 0.369 0.471
TDP1 protein and Viability (%) 60 nM TPT, n=6 0.358 0.485
TDP1/TOP1 and Viability (%) 120 nM TPT, n=10 0.199 0.582
Table 1: Summary of the Pearson’s correlation coefficient (r) and respective probability for all correlation analyses performed in the study.
and identify H69 and H187 cell lines as potential resources to further 
study the molecular basis of the repair of TOP1 breaks in SCLC.
Discussion
The highly proliferative and metastatic small cell lung cancers 
are routinely treated in the clinic with the camptothecin derivatives 
irinotecan and topotecan [7]. Though most patients initially respond 
to chemotherapy, virtually all patients experience rapid relapse 
and bad prognosis. Camptothecins induce damage to cancer cells 
by locking topoisomerase I (TOP1) on to DNA at single-strand 
breaks (SSBs) [9,12,17,34-36]. These SSBs can be converted to toxic 
DNA double-strand breaks by collision with the DNA replication 
machinery. Tyrosyl DNA phosphodiesterase 1 (TDP1) is a key player 
in the repair of TOP1 associated DNA breaks [16,18,19,37]. Loss of 
TDP1 has been shown to prolong the persistence of TOP1-SSBs and 
increases the likelihood of DNA double-strand break formation, 
thereby potentiating camptothecin-induced cytotoxicity. Many 
research groups are therefore keen to uncover small molecule TDP1 
inhibitors to improve the clinical response to camptothecin-based 
therapies. Despite the common use of camptothecin derivatives to treat 
SCLC in the clinic, the impact of TOP1 and TDP1 on the response 
of SCLC to camptothecins remains largely unknown. Furthermore, 
an understanding of the relationship between cellular TDP1 protein 
level, transcript level and catalytic activity in SCLC is also lacking. This 
knowledge is important for the design of practical diagnostic tools for 
patient tumor characterisation. 
In this study, we report a higher level of TDP1 expression in SCLC 
compared to other lung cancer cell lines and a remarkable variation 
in both TDP1 and TOP1 protein levels in SCLC. These data highlight 
SCLC as a key cancer type that may benefit from TDP1 inhibition. 
TDP1 protein level correlates well with both TDP1 mRNA and cellular 
TDP1 activity, as determined by two independent TDP1 activity assay 
methods. Although we found a good negative correlation between 
TOP1 levels and SCLC sensitivity to the camptothecin drug topotecan, 
we noted that TDP1 protein level alone did not correlate well with the 
sensitivity of SCLC cell lines to topotecan. Normalisation of TDP1 levels 
to that of TOP1 revealed a strong positive correlation to topotecan in 
80 % of the SCLC cell lines employed in the study. Interestingly, the two 
outlier cell lines (H69 and H187) that display relatively high sensitivity 
to topotecan possess remarkably higher levels of TDP1 than the rest. It 
is worth noting that TDP1 is not the only factor involved in the cellular 
response to topotecan and that redundant and partially overlapping 
pathways driven by TDP2, MUS81, XPF-ERCC1, and MRE11 are 
also implicated in this process [27,38,39]. It is possible that the H69 
and H187 cell lines lack one or more TDP1 alternative pathway for 
dealing with TOP1-breaks, which might account for their unexpected 
high sensitivity to topotecan. TDP1 posttranslational modification 
by phosphorylation, SUMOylation, and PARylation is important 
for recruitment and enrichment of TDP1 at sites of DNA damage 
[11,18,19,32], and it is thus possible that a lack of one or more of these 
modifications renders TDP1 less active in vivo in H69 and H187 cells, 
despite its higher expression level compared to the rest of the panel. A 
complete understanding of why these two cell lines are hypersensitive 
to CPT may furthermore reveal novel synthetic lethal targets for drug 
design and combination therapy with camptothecin treatments and 
will be the focus of further studies. 
The data presented here suggest the potential for utilising TDP1/
TOP1 ratio as an indicator for the response of SCLC to topotecan, 
however it will be important to additionally determine if this will hold 
true in patient SCLC tissues in future studies. Another important 
outcome of this study is the development and validation of an easy-to-
use TDP1 enzymatic assay in cell extracts, which could be exploited as a 
diagnostic tool in the clinic to stratify patients undergoing TOP1 based 
therapies. Furthermore, the strong correlation between TDP1 protein 
level, enzymatic activity, and mRNA level, suggest the potential utility 
of immunohistochemistry and microarray analysis in assessing TDP1 
levels in SCLC tissues.
In summary, we report a remarkable variation in TDP1 and TOP1 
levels in a panel of SCLC cell lines and suggest that SCLC could be an 
ideal model for confirming TDP1 inhibitor hits emerging from existing 
drug discovery projects and in future clinical trials. We additionally 
highlight the potential for TDP1/TOP1 ratio as a promising indicator 
for the response of SCLC to topotecan, though further work is required 
to confirm these findings in primary SCLC tissues. 
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